Few published clinical studies have found that breast cancer patients with BRCA1/2 mutations show better prognosis than control groups [24,25], while others have reported that they have worse survival outcomes [26,27,28], whereas some studies reported similar prognosis [29,30,31,32,33]. This evidence concerns the gene BRCA1 and breast carcinoma.